+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hospital-Acquired Infection Treatment Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780644
The global hospital-acquired infection treatment market size was valued at USD 15.31 billion in 2022 and is projected to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to reach a value of USD 22.17 billion by 2031. The market growth can be attributed to the increasing prevalence of hospital-acquired infections (HAIs) and the rising awareness about infection prevention and control measures.

Global Hospital-Acquired Infection Treatment Market: Introduction

Hospital-acquired infection treatment refers to the medical care provided to patients who have contracted infections while receiving treatment for other conditions within a healthcare facility. Common types of HAIs include urinary tract infections, surgical site infections, bloodstream infections, and pneumonia. Factors driving the demand for hospital-acquired infection treatment include the increasing number of hospitalizations, rising prevalence of antimicrobial-resistant pathogens, and growing awareness about the importance of infection control measures.

Advancements in technology have also played a significant role in the growth of the hospital-acquired infection treatment market. The development of novel diagnostic tools, antimicrobial coatings, and advanced sterilization techniques has contributed to the improvement of infection control measures. Furthermore, the implementation of electronic health records (EHR) and infection tracking systems has allowed healthcare facilities to monitor and manage infection rates more effectively. The hospital-acquired infection treatment market is expected to continue to grow in the coming years, as awareness of infection control measures increases, and new treatment options and technologies are developed to combat HAIs. However, there are still significant challenges to overcome, including the rapid emergence of antimicrobial resistance and the need for improved infection control practices in healthcare facilities, particularly in low- and middle-income countries.

Hospital-Acquired Infection Epidemiology

According to the World Health Organization, approximately 7 out of 100 hospitalized patients in high-income countries and 10 out of 100 hospitalized patients in low- and middle-income countries will acquire at least one HAI. The most common types of HAIs include urinary tract infections, surgical site infections, bloodstream infections, and pneumonia. These infections can lead to increased morbidity, mortality, and healthcare costs.

Hospital-Acquired Infection Treatment Market Segmentations

The market can be segmented based on products and services, infection type, application, end user, and major region:

Market Breakup by Product and Services

  • Sterilization
  • Cleaning and Disinfection Products
  • Protective Barriers
  • Endoscope Reprocessing Products

Market Breakup by Infection Type

  • Hospital-acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Urinary Tract Infections (UTIs)
  • Others

Market Breakup by Application Type

  • Drug-Resistance Testing
  • Disease Testing
  • Others

Market Breakup by End User

  • Hospitals and ICUs
  • Ambulatory Surgical and Diagnostic Centres
  • Nursing Homes and Maternity Centres

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Hospital-Acquired Infection Treatment Market Analysis

The global hospital-acquired infection treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of HAIs, rising awareness about infection prevention and control measures, and technological advancements in diagnostics and treatments.

North America is currently the largest market for hospital-acquired infection treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a well-established healthcare infrastructure, strong investment in research and development, and the implementation of stringent infection control guidelines.

Asia Pacific is another region that is experiencing significant growth in the hospital-acquired infection treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of HAIs, and the growing adoption of advanced diagnostic and treatment technologies. In addition, government initiatives to address infection control concerns are helping to drive the growth of the market in the region.

Key Players in the Global Hospital-Acquired Infection Treatment Market

The report provides a detailed analysis of the key players involved in the hospital-acquired infection treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • 3M
  • Belimed AG
  • Ecolab Inc
  • Fortive
  • Getinge AB
  • Bayer AG
  • Danaher
  • Novartis AG
  • Merck & Co., Inc
  • Abbott
  • Pfizer Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology3 Executive Summary
4 Hospital-Acquired Infection Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Hospital-Acquired Infection Treatment Market
8.1 Global Hospital-Acquired Infection Treatment Market Overview
8.2 Global Hospital-Acquired Infection Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Hospital-Acquired Infection Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Hospital-Acquired Infection Treatment Market Forecast Value (2023-2031)
8.2.2 Global Hospital-Acquired Infection Treatment Market by Products and Services
8.2.2.1 Market Overview
8.2.2.1.1 Sterilization
8.2.2.1.1.1 Sterilization Products
8.2.2.1.1.1.1 Heat Sterilization Equipment
8.2.2.1.1.1.2 Low-Temperature Sterilization Equipment
8.2.2.1.1.1.3 Radiation Sterilization Equipment
8.2.2.1.1.1.4 Other Sterilization Equipment
8.2.2.1.1.2 Contract Sterilization Services
8.2.2.1.1.3 Sterilization Consumables and Accessories
8.2.2.1.2 Cleaning and Disinfection Products
8.2.2.1.2.1 Disinfectants
8.2.2.1.2.2 Disinfectors Equipment
8.2.2.1.2.3 Others
8.2.2.1.3 Protective Barriers
8.2.2.1.4 Endoscope Reprocessing Products
8.2.3 Global Hospital-Acquired Infection Treatment Market by Infection Type
8.2.3.1 Market Overview
8.2.3.1.1 Hospital-acquired Pneumonia
8.2.3.1.2 Bloodstream Infections
8.2.3.1.3 Surgical Site Infections
8.2.3.1.4 Gastrointestinal Infections
8.2.3.1.5 Urinary Tract Infections (UTIs)
8.2.3.1.6 Others
8.2.4 Global Hospital-Acquired Infection Treatment Market by Application
8.2.4.1 Market Overview
8.2.4.1.1 Drug-Resistance Testing
8.2.4.1.2 Disease Testing
8.2.4.1.3 Others
8.2.5 Global Hospital-Acquired Infection Treatment Market by End User
8.2.5.1 Market Overview
8.2.5.1.1 Hospitals and ICUs
8.2.5.1.2 Ambulatory Surgical and Diagnostic Centres
8.2.5.1.3 Nursing Homes and Maternity Centres
8.2.6 Global Hospital-Acquired Infection Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America Hospital-Acquired Infection Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Hospital-Acquired Infection Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Hospital-Acquired Infection Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Hospital-Acquired Infection Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Hospital-Acquired Infection Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Hospital-Acquired Infection Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 3M
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Belimed AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Ecolab Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Fortive
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Getinge AB
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Bayer AG
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Danaher
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Novartis AG
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Merck & Co., Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Abbott
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Pfizer Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Hospital-Acquired Infection Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Companies Mentioned

  • 3M
  • Belimed AG
  • Ecolab Inc.
  • Fortive
  • Getinge AB
  • Bayer AG
  • Danaher
  • Novartis AG
  • Merck & Co., Inc.
  • Abbott
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information